Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 334 followers
Latest posts
Last updated about 2 hours ago
BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3
about 2 hours ago
Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with...
Xenon phase 3 epilepsy readout 'blows away' expectations, stock soars
about 2 hours ago
Xenon Pharmaceuticals’ anti-seizure candidate has smashed a pivotal trial out of the...
FDA greenlights backup anti-choking suction device
about 3 hours ago
With a plungerlike handle and an air mask placed over the nose...
Tenacia builds $308M biobucks deal with Rapport to develop epilepsy drug in greater China
about 3 hours ago
Shanghai-based Tenacia Biotechnology is making a $308 million biobucks move for a...
AbbVie ties $350M amylin bet to almost 10% weight loss after 12 weeks
about 3 hours ago
AbbVie has unveiled the first data from its $350 million obesity bet...
Pfizer ramps up plans for trispecific after phase 2 eczema win
about 4 hours ago
Pfizer is ramping up plans for tilrekimig after a phase 2 win...
Regeneron's obesity drug shows Zepbound-like efficacy in phase 3
about 5 hours ago
Regeneron’s Chinese partner reported Zepbound-like efficacy in a phase 3 trial, de-risking...
Italy's Alfasigma pens $690M deal for GSK itching drug awaiting FDA approval decision
about 6 hours ago
Italian pharma Alfasigma is handing $300 million to GSK for an itching...
Roche’s oral SERD flunks phase 3 trial in 1st-line breast cancer, raising questions of mechanism's limits
about 7 hours ago
A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients...
FDA’s Vinay Prasad to depart agency at the end of April
3 days ago
After a tumultuous tenure marked by recent clashes with the biopharma industry...
FDA to end 9-month advisory committee drought with April review of AstraZeneca’s oral SERD, Truqap
3 days ago
The FDA is ending a roughly eight-month hiatus of drug-related advisory committee...
Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda
3 days ago
Servier on Friday unveiled a deal to acquire Day One Biopharmaceuticals—a commercial-stage...